

VU Research Portal

The Keratocystic Odontogenic Tumor

Amaral Mendes, R.A.

2011

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Amaral Mendes, R. A. (2011). *The Keratocystic Odontogenic Tumor: Clinical Behaviour and Role of COX-2 in the Biological Pathways*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Summary and conclusions

Cyclooxygenase-2 (COX-2) levels are increased in various tumors, particularly those involving the esophagus, stomach, breast, pancreas, lung, colon, skin, urinary bladder, prostate and head and neck. The tumorigenic mechanisms of COX-2 overexpression still remain poorly understood and may include mechanisms that act at different stages of the disease. The literature shows increasing evidence that overexpression of COX-2 plays an important role in tumor growth and spread of tumors by interfering with different biological processes such as cell proliferation, cell adhesion, immune surveillance, apoptosis, and angiogenesis^{1,2,3,4,5,6}. The expression of COX-2 might shed some light over the physiopathology and clinical behaviour of tumors of the head and neck, including benign odontogenic neoplasms of the jaws with an aggressive behaviour, such as keratocystic odontogenic tumors (KCOTs).

In the classification of Head and Neck Tumors published in 2005 by the World Health Organization (WHO), the previously designated “parakeratinized odontogenic keratocyst” has been reclassified as a benign intraosseous neoplasm, naming it “KeratoCystic Odontogenic Tumor” (KCOT), due, among other things, to its sometimes aggressive behaviour leading to high recurrence rates. Cystic lesions lined by orthokeratinizing epithelium were excluded by the WHO from the diagnosis of KCOT. This variant is now known as an orthokeratinized odontogenic cyst⁷.

The recurrence rate after conservative surgical treatment, without adjunctive treatment, of the KCOT has been studied in a total number of 68 patients from the Department of Oral and Maxillofacial Surgery/Pathology of the Vrije Universiteit medical center (VUmc)/ ACTA, previously untreated and fulfilling the histopathological criteria provided by the 2005 WHO classification. The study period lasted from 1975 to 2009. Treatment consisted of either enucleation or marsupialization; the mean follow-up period was 65 months. No involved or adjacent teeth were removed, except for wisdom teeth and badly decayed teeth. After enucleation, the recurrence rate was 20.7% in a mean follow-up period of 46 months, while 40% of the marsupialized KCOTs recurred in a mean follow-up period of 58 months. In none of the patients permanent loss of nerve function has been observed.

Due to the recurrence rate observed in the present study, and in view of the potential benefit of adjunctive treatment in KCOT, particularly with regard to the use of Carnoy's solution, we performed a review of the various treatment modalities, ranging from simple enucleation to radical surgery. As it was also confirmed in a recent Cochrane study⁸, no scientific evidence was found for the adjunctive use of Carnoy's solution with regard to the risk of recurrence. Furthermore, no prognostic factors based on clinicopathologic and immunohistochemical findings for determining the potential for recurrence of KCOT are available yet.

A review of the histopathological features and biological behaviour of this recognized aggressive pathological entity of the jaws and a contemporary outline of the molecular (growth factors, p53, PCNA and Ki-67, bcl-2) and genetic (PTCH, SHH) alterations associated with this odontogenic neoplasm has provided a thorough understanding of the physiopathological mechanisms involved in the development of this neoplasm of the jaws. There are, indeed, significant differences on the molecular level between KCOT and other odontogenic cystic lesions, suggestive of a different biological behaviour^{7,9}.

The current knowledge of the overall role known to be played by COX-2 in tumorigenesis suggest that COX-2 may be an important marker involved in the biological behaviour of the KCOT. Therefore, we performed a study to assess the expression of COX-2 in 116 specimens of KCOTs retrieved from the files of the Department of Oral and Maxillofacial Surgery/Pathology of the Vumc/ACTA. Mild to strong expression of COX-2 was observed in 83 (71,6%) cases, 34 (29,3%) of which were mildly positive and 49 (42,2%) were strongly positive. COX-2 stain was detected mainly in the epithelial lining. The expression of COX-2 in KCOTs and the current knowledge of the role played by COX-2 in tumorigenesis further strengthen the concept that the KCOT should be regarded as a neoplasm.

Although COX-2 has rarely been used to assess the biological activity of the KCOT, our comparative results involving p53, Ki-67 and COX-2 found no statistically relevant difference between the molecular expression of these markers.

We have also carried out a study in 10 dentigerous cysts to assess the expression of COX-2 and found a positive expression of COX-2 in 6 out of the 10 dentigerous cysts. These results - not published - substantiate the hypothesis that SHH may in fact be an instigating factor behind developmental cysts, with concomitant aberrant expression of molecular markers being the

natural consequence not of genetic changes but rather of an amplified physiological process, thus leading to expression of COX-2 in developmental cysts, such as dentigerous cysts.

In fact, Zhang et al have recently reported immunoreactivity for SHH, PTCH, SMO, and GLI1 in the epithelial cytoplasm of dentigerous and glandular odontogenic cysts¹⁰. Pavelić et al, have also reported evidence of PTCH expression in dentigerous cyst lining, with loss of heterozygosity (LOH) for the D9S287 marker and/or D9S180 marker in about 50% of dentigerous cysts, substantiating a more direct argument for PTCH involvement in cystic growth¹¹. On the other hand, Barreto et al found no correlation between the immunoreactivity of PTCH in the superficial epithelial layers of odontogenic cysts and an actual mutation of the PTCH as assessed by direct sequencing¹². Moreover, both p53 and Ki-67 have also been previously reported to be overexpressed in developmental cysts such as dentigerous cysts⁹. Therefore, despite the important role played in the molecular network responsible for odontogenic tumorigenesis, SHH also plays a relevant role in odontogenesis, which may support Pavelić's hypothesis that the malfunctioning pathway might be the cause of either DC or KCOT growth¹¹. However, these results could explain why the cases reporting carcinomatous changes in the epithelium of odontogenic cysts/tumors involve mainly KCOTs and dentigerous cyst¹³⁻²¹.

The multitude of markers known to be overexpressed in KCOTs is suggestive of what could be called a "network addiction" pattern, rather than a pathological mechanism dependant on a specific activated/suppressed gene, thus explaining its aggressive behaviour. The key element for future management of the KCOT will probably be based on thorough knowledge of the biological basis of this tumor, thereby enabling a more tailored treatment approach. In fact, there are rather toxic drugs against p53, SMO or EGFR being used in the treatment of tumors. By providing a new molecular target, one may use drugs aimed at COX-2 as an adjunctive therapy, thus circumventing more aggressive surgical treatments and decreasing the risk of recurrences.

Bibliography

- 1 - Mohan S, Epstein JB. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. *Oral Oncol* 2003; 39: 537-46
- 2 - Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. *Head Neck* 2002; 24: 792-9
- 3 - Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck cancer. *Cancer Res* 1999; 59:991-4
- 4 - Mestre JR, Subbaramaiah K, Sacks PG, Stimson P, Schantz SP, Tanabe T, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. *Cancer Res* 1997; 57: 2890-5
- 5 - Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. *Cell* 1995; 83: 493-501
- 6 - Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. *J Clin Invest* 2000; 105: 1589-94
- 7 - Barnes L, Eveson JW, Reichart P, et al. World Health Organization classification of tumors. Pathology and genetics of head and neck tumors. IARC Press: Lyon; 2005
- 8 - Sharif FNj, Oliver R, Sweet C, Sharif MO. Interventions for the treatment of keratocystic odontogenic tumors (KCOT, odontogenic keratocysts (OKC)). *Cochrane Database Syst Rev* 2010 Sep 8;(9):CD008464
- 9 - Shear M. The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 2: proliferation and genetic studies. *Oral Oncol* 2002; 38: 323-31

- 10 - Zhang L, Sun ZJ, Chen XM, Chen Z. Immunohistochemical expression of SHH, PTC, SMO and GLI1 in glandular odontogenic cysts and dentigerous cysts. *Oral Dis.* 2010; 16: 818-22
- 11 - Pavelić B, Levanat S, Crnić I, Kobler P, Anić I, Manojlović S, Sutalo J. PTCH gene altered in dentigerous cysts. *J Oral Pathol Med.* 2001; 30: 569-76
- 12 - Barreto DC, Bale AE, De Marco L, Gomez RS. Immunolocalization of PTCH protein in odontogenic cysts and tumors. *J Dent Res* 2002; 81: 757-60
- 13 - Makowski GJ, McGuff S, Van Sickels JE. Squamous cell carcinoma in a maxillary odontogenic keratocyst. *J Oral Maxillofac Surg* 2001; 59: 76-80
- 14 - Anand VK, Arrowood Jr JP, Krolls SO. Malignant potential of the odontogenic keratocyst. *Otolaryngol Head Neck Surg* 1994; 111: 124-9
- 15 - Areen RG, McClatchey KD, Baker HL. Squamous cell carcinoma developing in an odontogenic keratocyst. *Arch Otolaryngol* 1981; 107: 568-9
- 16 - Foley WL, Terry BC, Jacoway JR. Malignant transformation of an odontogenic keratocyst: report of a case. *J Oral Maxillofac Surg* 1991; 49: 768-71
- 17 - MacLeod RI, Soames JV. Squamous cell carcinoma arising in an odontogenic keratocyst. *Br J Oral Maxillofac Surg* 1988; 26: 52-7
- 18 - Moos KF, Rennie JS. Squamous cell carcinoma arising in a mandibular keratocyst in a patient with Gorlin's syndrome. *Br J Oral Maxillofac Surg* 1987; 25: 280-4
- 19 - Norris LH, Baghaei-Rad M, Maloney PL, et al: Bilateral maxillary squamous odontogenic tumors and the malignant transformation of a mandibular radiolucent lesion. *J Oral Maxillofac Surg* 1984; 42:827-34

20 - Gulbranson SH, Wolfrey JD, Raines JM, McNally BP. Squamous cell carcinoma arising in a dentigerous cyst in a 16-month-old girl. *Otolaryngol Head Neck Surg* 2002; 127: 463-4

21 - Yasuoka T, Yonemoto K, Kato Y, Tatematsu N. Squamous cell carcinoma arising in a dentigerous cyst. *J Oral Maxillofac Surg* 2000; 58: 900-5